Moderators: 4OurRetirement
Search This Board: 
Created: 11/07/2003 12:50:05 AM - Followers: 835 - Board type: Free - Posts Today: 4

Avid Bioservices, Inc. (Nasdaq “CDMO”), Tustin CA.
President/CEO: Nicholas Green (eff. 7-30-20 )
Four Avid Fact Sheets a/o 2-2020:
Avid Bioservices is a CDMO committed to improving the lives of patients by manufacturing products derived from mammalian cell culture for the biotechnology & biopharmaceutical industries. Services include cGMP clinical & commercial product manufacturing, purification, bulk packaging, stability testing & regulatory strategy, submission, and support. The company also provides a variety of process development activities, including cell line development & optimization, cell culture & feed optimization, analytical methods development, and product characterization.

12-2019/Video: Tour of Myford Facility (2mins.):
7-2020: AVID’s Push Towards cv19 (I don’t capitalize things I hate) contracts:

Sep1(Tue): Q1/FY21 (qe 7-31-20) Financials & Conf. Call - Transcript:
Sep17/Fireside Chat w/Nick Green: 18th Annual Morgan Stanley Global Healthcare Conf.:
Sep21-24/Virtual: Biotech Week Conf., Boston
Sep21-24/Virtual: BioProcess Intl. US Wes Conf., Santa Clara CA

...Time TBD: Presentation by Haiou Yang, PhD "Facility-Fit Driven Dev. for a mAb Production Process"
Oct20 10amPT/VIRTUAL: Annual Shareholders Mtg.  14A Proxy:
...ASM Replay (9:45): (Control# not needed)
Apr20-22 2021/Booth#1159: INTERPHEX, NYC

Dec2(Wed) after mkt: Q2/FY21 (qe 10-31-20) Financials & Conf. Call - Transcript:
Dec14-17: Antibody Engineering & Therapeutics Conf., San Diego

Quotes: Yahoo: Nasdaq: RT:
IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401, Tim Brons (Media) 415-675-7402

Latest 10Q 10-31-20 iss. 12-2-20 (Cash 10-31-20=$35.7mm)
Latest 10K 4-30-20 iss. 6-30-20 (Cash 4-30-20=$36.3mm)
Latest DEF14A/Proxy iss. 8-27-20 (re: 10-20-20 ASM):
ALL SEC filings for CDMO:
CDMO's Corp. Bylaws (a/o 11-14-14):
Poison Pill adopted 3-16-06 for 10yrs: 44-pg SEC filing: BUNGLER explains in plain language:
...3-17-16 Poison Pill extended until 3-16-2021 (Form8A Amendment #1)
...Poison Pill TERMINATED eff. 9-23-2019

Shares O/S as of 11-23-20=56,726,334 - history since 4-2006: (at bottom)
...A/O 10-31-20: 3,451,000 stock options outstanding at a wgt.avg. exercise price of $6.41 (pg.16 10Q). for CDMO (shows Float):
1-12-18: S-3 Shelf Registration filed for up to $125mm
...12-14-20: Avid raises ~$34M gross, selling 3,833,335@9.00/sh. (underwriter: RBC Capital)
...2-20-18: Avid Raises ~$21.8M net, selling 10,294,445@$2.25 (underwriter: Wells Fargo) 8-K: 424B5:

Total INST.+LARGE Holdings now 41,617,965 73.5% a/o 9-30-20

1. Eastern Capital (Kenneth Dart): 4,300,992 7.6% (a/o 8-21-19 14A/Proxy: – orig. 13G filed 11-2015)
2. Tappan Street (Prasad Phatak): 4,285,000 7.6% (a/o 12-31-19 13G: )
3. Blackrock Inc. (Larry Fink): 3,834,816 6.8% (-111,172 a/o 9-30-20 Nasdaq Inst.)
4. IsZo Capital Mgt. (Brian Sheehy): 3,459,888 6.1% (-88,144 a/o 9-30-20 Nasdaq Inst.)
5. Millennium Mgt. 2,678,984 4.7% (+633,918 a/o 9-30-20 Nasdaq Inst.)
6. Vanguard Group 2,659,738 4.7% (-19,553 q/e 9-30-20 Nasdaq Inst.)
7. Snyder Capital 2,302,621 4.1% (-2,258 a/o 9-30-20 Nasdaq Inst.)
8. Altravue Capital 1,973,349 3.5% (+39,534 a/o 9-30-20 Nasdaq Inst.)
9. Wellington Mgt. 1,503,162 2.7% (+236,947 a/o 9-30-20 Nasdaq Inst.)
10. Sargent Invest. Grp. 1,052,099 1.9% (-11,000 a/o 9-30-20 Nasdaq Inst.)
11. State Street 992,280 1.8% (-65,922 a/o 9-30-20 Nasdaq Inst.)
12. Portolan Capital 963,374 1.7% (+528,662 a/o 9-30-20 Nasdaq Inst.)
13. Silvercrest Asset Mgt. 878,805 1.6% (-16,746 a/o 9-30-20 Nasdaq Inst.)

Inst. Holdings (Nasdaq) - updated 45-days after each qtr-end:
INSIDER-Trans:  (formerly PPHM thru 2017: )
Short Interest, updated twice a month:
A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh):
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24)
PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20)
Potential Value: 9-19-2017: Catalent acquires CDMO Cook Pharmica for $950M ($179Msales x 5.3; EV/EBITDA=17.3)

AVID TEAM: - Open Jobs:
7-30-20: Nicholas Green (ex-Therapure Biopharma) becomes President/CEO of Avid - 6-25-20 PR:
4-13-20: Avid Hires 2 Senior Directors of Bus. Dev: Jason C. Brady & Sylvia Hinds
1-8-20: Avid Appoints Timothy Compton as Chief Commercial Officer (repl. Tracy Kinjerski)

7-26-19: Catherine Mackey, PhD (ex Pfizer VP) joins Avid's BOD, replacing Joel McComb
5-8-19: Richard (Rick) B. Hancock named Interim President/CEO; Roger Lias resigns
7-16-18: Daniel Hart (ex-ENO Holdings) joins Avid as CFO
7-16-18: Michael Faughnan (ex-Lonza/WuXi Biologics) joins Avid as Sr.Dir./BusDev/WestC (Left 5-2019)
5-29-18: Sandra C. Carbonneau (ex-Lonza) joins Avid as Dir./BusDev./EastCoast (left 12-2019)

5-8-18: Magnus Schroeder (ex-AGC Biologics) joins Avid as VP/Process Sciences
2-23-18: CFO Paul Lytle voluntarily resigns eff. 5-24-18 (2-23-18 +90days), "CFO search underway"
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s CEO and join PPHM’s BOD eff. 9-25-17 (left 5-8-19)
11-29-17: Tracy L. Kinjerski joins Avid as VP/Bus.Operations (Left 1-8-2020)
Profiles of all 7 BOD members:
...Joseph Carleone/Chair, Nicholas Green(CEO), Richard Hancock, Gregory Sargen, Mark Bamforth, Patrick Walsh, Catherine Mackey

10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s”
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs"

Also see:
Janney Montgomery Scott - Paul Knight PT=$10
H.C. Wainwright & Co. - Joseph Pantginis PT=$9
Craig-Hallum Capital Group - Matt G. Hewitt PT=$10
First Analysis Securities - Joseph Munda PT=$7.50
Stephens Inc. - Jacob Johnson PT=11 (10=>11 9-2-20)

2-3-21: Avid to Mfg. CV19 Therapeutic Lenzilumab for Humanigen
8-26-20: Mapp Biopharmaceutical signs w/Avid for ClinDev of Antiviral Antibody (MBP091) BARDA #HHSO100201900018C($16.5M+Opt/$30M), see:
8-20-20: Oragenics signs Dev/Mfg Agreement with Avid for COVID-19 Vaccine “TerraCoV2”
8-6-20: Iovance Biotherapeutics signs w/Avid(+Aragen) to Dev+Mfg. IOV-3001 (IL-2 Analog)
7-28-20: Avid Teams with Argonaut to add “Parenteral Fill-Finish Services”
5-6-20: Avid Teams with Aragen to speed up drug dev./delivery timelines
4-23-20: Avid receives $4.4M PPP/CV19 Loan (can apply for forgiveness) 8K:
...5-12-20: Avid Pays Back $4.4M PPP/CV19 Loan (“New SBA Guidance/abundance of caution”) 8K:
3-10-20: CDMO's Revs & Burns By Qtr Table, FY07/Q1 thru FY20/Q3 (q/e 1-31-20):
......Avid FY20 (fye 4-30-20) revenues guidance: $55-59M; committed backlog=$58mm at 1-31-2020.
7-8-19: Avid Signs New Top10 Global Pharma and Expands Existing Cust. Relationship
6-27-19: "The 5 new clients signed in late FY2018 contributed significantly to revenue diversification in FY2019." SEE CUST SPLITS for FY19:
4-24-18: ”In recent weeks, Avid has signed new agreements with 3 addl. undisclosed intl. drug dev. companies (that’s 4 thus far in CY2018)”
3-1-18: Acumen Pharm. selects Avid for Process Dev. & Mfg. of ACU193 (Alzheimer’s)
2-21-18: Enzyvant selects Avid to commercially mfg. RVT-801 (Farber disease)
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones
...NOTE: 2-13-18: Oncologie Licenses Mologen’s immunotherapeutic ‘lefitolimod’ (TLR9 agonist) “ONCOLOGIE is backed by top-tier intl. investors and has the objective to dev. novel personalized medicines in the field of immuno-oncology."
2-28-17: Avid & Cook (acq. by Catalent 12-2017 for $950M; $179Msales x 5.3; EV/EBITDA=17.3) remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”):

10-8-19: Avid Announces Completion of Expansion of Process Dev. Capabilities & Labs
...will “significantly accelerate Avid’s ability to drive efficient & rapid on-boarding of new cust. pgms progressing to mfg.”
4-24-18: Avid adding Process Dev. Labs, upgrading capabilities (in phases; total will be >6000sq; 1st one ready Q3CY18/Jul-Sep'18)
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L".
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17:
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
6-2-16: Corp.Update – Avid Expansion & Drug Development -
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs)
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion
12-10-14: Avid to Double Mfg. Capacity(“Myford Expansion”) &

Sep17/Fireside Chat w/Nick Green: 18th Annual Morgan Stanley Global Healthcare Conf.:
5-18-20: Avid Listed In Top CMO Awards Article
...”Avid received 5 CMO Leadership Awards categories, incl. 2 Champion designations: Expertise & Service.”
10-25-18/BioPharma: Roger Lias Interview, “Avid expansion to Triple Process Dev. Capacity”
Sept2018/BioTechWEEK: Tracy Kinjerski (VP/BusOP) interview: Avid’s differentiators (6mins.)
1-29-18: NobleCon14 - 14th Annual Inv. Conf., Ft.Laud. => Roger Lias' webcast/slideshow
11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias

12-2-20: Qtly. Conf. Call (Green/Hart/Compton) PR & Transcript
10-20-20 Annual Shareholders Meeting - Replay (9:45): (Control# not needed)
9-1-20: Qtly. Conf. Call (Green/Hart/Compton) PR & Transcript
...CEO N.Green: ”My first few weeks have done nothing but confirm my view that I believe Avid to be a strong and state-of-the-art company with significant opportunity for growth."
6-30-20: Qtly. Conf. Call (Hancock/Hart/Compton) PR & Transcript
...RickH: "Based on our customers' growing demand and our expanding business development activity, we believe that we will significantly increase capacity utilization in 2021 and beyond. Accordingly, we have entered into a new phase of planning for the expansion that will support our growing business in the years to come.”
...”Top10 Pharma customer added 7-2019 named in 10-K: GILEAD SCIENCES.”

3-10-20: Qtly. Conf. Call (Hancock/Hart/Compton) PR & Transcript
12-9-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript

9-5-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript
6-27-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript
...Rick Hancock, "Most importantly, during Q4, the Company achieved positive income, generating cash from dev. & mfg. operations for the 1st time since the beginning of the CDMO transition (Jan'18)."
3-11-19: Qtly. Conf. Call (Lias/Hart) PR & Transcript
12-3-18: Qtly. Conf. Call (Lias/Hart//Kinjerski) PR & Transcript
10-4-18: ASM/2018 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Report
9-10-18: Qtly. Conf. Call (Lias/Hart) PR & Transcript
...Roger Lias, "During the qtr, we advanced the projects of our existing active clients and continue to engage with numerous potential new customers."
7-16-18: Qtly. Conf. Call (Lias/Kinjerski) PR & Transcript
...Roger Lias, “In a short period, we’ve established a targeted business dev. operation that is actively providing visibility for Avid Bioservices within our fast growing but competitive marketplace.”
3-12-18: Qtly. Conf. Call (Lias/Kinjerski/Lytle) PR & Transcript
...Roger Lias, ”I'm pleased to be able to report that in a very short period of time we've generated significant interest from both emerging & growth biopharmaceutical players and from pharmaceutical multinationals. I'm confident that the plan we're executing will drive a considerable increase in backlog and the opportunity to further enhance capacity utilization in the future.”
......From the 3-12-18 PR: “At present, we are in late-stage negotiations with several potential new customers and expect to announce the executed agreements before the end of the FY[4-30-18].”
1-18-18: ASM/2017 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Reports 12-7-17 PROXY/14A:
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript
...Roger Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript
...Steve King: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript
...Steve King: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript
...Steve King: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript
...Steve King: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 ASM/2016: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast:

Feb. 2018: Peregrine Pharmaceuticals completed its Mid’17-Early’18 Transition to a Pure-Play CDMO
(Contract Development & Manufacturing Organization), Avid Bioservices, Inc. - CEO: Roger Lias.

**FULL PPHM=>CDMO Transition History (Ronin/SWIM):
1-8-17: Peregrine chgs. name to “Avid Bioservices, Inc.”; new ticker: “CDMO” (+CDMOP)
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones
...12-13-18/8-K: Overview of Oncologie sale:
NOTE: “PS-targeting Exosome tech. not included; back to UTSW", see:

Click here for an ARCHIVE of the History of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, and Activity over the years, from early 2000’s thru 2017, prior to being Sold to ONCOLOGIE:
Of Interest (post Oncologie Sale):
Oncologie's website:

4-20-18/AACR’18: MSKCC(LudwigCC) Tweets about 2 WolchokLAB/”PPHM” Anti-PS Posters
4-26-18: New Bavi+Keytruda/LIVER Ph2 IST Trial, Sponsor=UTSW, Collab=MERCK
6-7-18: Oncologie Obtains $16.5M Seed Funding Led by Pivotal bioVenture Partners China Fund
6-7-18/BioCentury: Laura Benjamin states, “Oncologie plans to begin a trial mid-summer '18 evaluating Bavi to treat HCC and a P-O-C trial in Gastric cancer in 1Q19/2Q19.”
12-3-18: During q/e 10-31-18, Avid sold remaining legacy R&D asset, r84(anti-VEGF), to Oncologie for $1.0M upfront. Avid is eligible to receive up to an addl. $21M in dev/reg./comm. milestones, and low to mid-single digit royalties on net sales upon commercialization of products utilizing r84
11-4-19/PharmaBoardroom: Interview with Oncologie CEO Laura Benjamin discussing the 2 ongoing Bavi Trials w/Keytruda (USA UK Taiwan S.Korea)
...Dr. Benjamin,
"We have high expectations of bavituximab and have obtained the global rights for this compound."

...Ongoing Trial #1 (N=80): Open Label, Bavi+Keytruda Adv. Gastric/GEJ Cancer
......1-17-2020 ASCO/GI Poster:
...Ongoing Trial #2 (N=34 UTSW): Open Label, Bavi+Keytruda Adv. Hepatocellular Carcinoma
6-11-20/Fiercebiotech: Oncologie Reels In $80M To Push Clinical Pgms/Build Pipeline &

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
Institutional Investors (As Previously Posted By CJGaddy On11/17/2020)... 4OurRetirement 12/30/2020 11:28:42 PM
I would put more of the blame on vinmantoo 06/25/2022 01:38:29 PM
I agree wholeheartedly. Those stimulus checks likely had vinmantoo 06/25/2022 01:13:03 PM
Increase in M1 money supply isn't just spending djohn 06/25/2022 08:33:36 AM
djohn, the dollar hasn't been has strong as Protector 06/25/2022 06:00:14 AM
Well said. Looking forward to how they finished corporalagarn 06/24/2022 06:09:34 PM
I agree wholeheartedly. Those stimulus checks likely bfiest 06/24/2022 05:52:33 PM
I was pretty good in Economics. The corporalagarn 06/24/2022 01:29:43 PM
About “decisions”(not economically related), is there any correlation north40000 06/24/2022 12:39:28 PM
Root cause of inflation? energy? djohn 06/24/2022 12:24:28 PM
We'll just have to disagree on that dorf1 06/24/2022 12:16:31 PM
Corp you’re making too much sense. Stop bfiest 06/24/2022 11:54:47 AM
I was being facetious. One man isn't corporalagarn 06/24/2022 11:54:35 AM
Corp, my thoughts exactly. The root cause of dorf1 06/24/2022 11:47:11 AM
I would put more of the blame on corporalagarn 06/24/2022 10:55:36 AM
And bull markets never end? cheynew 06/24/2022 10:42:01 AM
That’s logical. I’m hoping we’ve seen the bfiest 06/24/2022 09:22:40 AM
Please explain why the value of our investments corporalagarn 06/24/2022 09:15:37 AM
tech0200, that is the problem about the deal Protector 06/24/2022 05:21:42 AM
4OurRetirement, your sources on those break-out seem to Protector 06/24/2022 05:17:07 AM
Yes but I like to see them pay tech0200 06/24/2022 01:34:11 AM
Will There Be Any Large AfterHour Postings Tomorrow… 4OurRetirement 06/23/2022 11:23:13 PM
I understand the policy of staying on topic djohn 06/23/2022 06:10:16 PM
Time Price Shares Exch/Mkt 06/23/2022 16:13:39 EDT I 16.51 2 ARCA cheynew 06/23/2022 04:38:46 PM
FWIW, ThinkOrSwim Suddenly Shows Potential +/-$7.10 MarketMakerMove! Glta,eom. 4OurRetirement 06/23/2022 04:29:48 PM
Is $CDMO AboutTo BreakOut In AfterMarket??? I See... 4OurRetirement 06/23/2022 04:15:51 PM
Please Continue To Post About AvidBioservices, But Try… 4OurRetirement 06/23/2022 03:57:48 PM
Sorry, I will go back in my lurking dorf1 06/23/2022 03:29:06 PM
EarningsReport Approaching. Can We Keep Posts About $CDMO?(Thanks!)Glta,eom. 4OurRetirement 06/23/2022 02:36:14 PM
Just stop. cheynew 06/23/2022 02:13:39 PM
Sometimes you guy talk in riddles that sound Protector 06/23/2022 11:23:25 AM
r, those IIs are engaged in "manufacturing married swg_tdr 06/23/2022 10:00:54 AM
The lull ended on inst 116.42% with r622102675 06/23/2022 08:33:17 AM
Avid Bioservices to Report Financial Results for Quarter cheynew 06/22/2022 04:06:56 PM
“CONFIRMED breakout above 14.43, no resistance in area…” vinmantoo 06/22/2022 12:56:57 PM
Sold a bit at 14.61 and wrong... Still. EndoTarget 06/22/2022 12:31:11 PM
“CONFIRMED breakout above 14.43, no resistance in area…” 4OurRetirement 06/22/2022 10:47:19 AM
Sure was...think a bank would have a problem r622102675 06/22/2022 08:54:54 AM
I think it was option exercise. cheynew 06/22/2022 08:50:12 AM
Ziebell buys his 6428 shrs outright...not a bad r622102675 06/22/2022 08:48:52 AM
Will $CDMO Have HighVolume Close Like Friday?:-) Glta,eom. 4OurRetirement 06/21/2022 02:24:17 PM
“ WATCH for possible breakout above 14.76” According To:… 4OurRetirement 06/21/2022 01:47:39 PM
Moving with the market. I just don't dorf1 06/21/2022 01:09:28 PM
Will $CDMO Issue PR AfterClose Regarding EarningsReportDate? Glta,eom. 4OurRetirement 06/21/2022 11:21:36 AM
#342216 years now I keep saying to some Protector 06/18/2022 06:14:59 AM
A little of subject. horselover45 06/17/2022 11:53:32 PM
Or,(Maybe?), News HasLeaked That RussellRebalancing Plans To Increase… 4OurRetirement 06/17/2022 08:56:27 PM
There were only 74 calls in the money. cheynew 06/17/2022 08:45:57 PM
Basically 1.6 MillionShares Traded Today (Mostly Around Close)… 4OurRetirement 06/17/2022 08:41:06 PM
Total options expiration day volume close to 1.6 Mill...... ElSid18 06/17/2022 04:03:43 PM
06/17/2022 16:00:00 EDT X 13.34 814776 NSD cheynew 06/17/2022 04:01:09 PM
Post Subject